Cold spring harbor laboratory (Plus de 4 700 résultats)

Hardback. Etat : Very Good. Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…

Etat : Good. Good condition ex-library book with usual library markings and stickers.

Etat : Acceptable. Item in acceptable condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Etat : very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Etat : very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

paperback. Etat : Fair.

Hardback. Etat : Good. Most people who do a PhD and postdoctoral work in the biomedical sciences do not end up as principal investigators in a research lab. Despite this, graduate courses and postdoctoral fellowships tend to focus almost exclusively on training for bench science rather than other career paths. This book plugs the gap by providing information about a wide variety of different careers that individuals with a PhD in the life sciences can pursue. Covering everything from science writing and grant administration to patent law and management consultancy, the book includes firsthand accounts of what the jobs are like, the skills required, and advice on how to get a foot in the door. It will be a valuable resource for all life scientists considering their career options and laboratory heads who want to give career advice to their students and postdocs.…

Paperback. Etat : Good.

Hardback. Etat : Good. Twenty-four true, wide-ranging tales of crime, history, human behavior, illness, and ethics, told from the personal perspective of the author, an eminent physician-lawyer who uses the stories to illustrate the principles of human genetics and to discuss the broader issues.

Etat : acceptable. This copy has clearly been enjoyedâ"expect noticeable shelf wear and some minor creases to the cover. Binding is strong, and all pages are legible. May contain previous library markings or stamps.

paperback. Etat : Very Good.

hardcover. Etat : Very Good.

Etat : good. Fast Free Shipping â" Good condition. It may show normal signs of use, such as light writing, highlighting, or library markings, but all pages are intact and the book is fully readable. A solid, complete copy that's ready to enjoy.

Paperback. Etat : Very Good. 1. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Etat : Good. . . Before placing your order for please contact us for confirmation on the book's binding. Check out our other listings to add to your order for discounted shipping. All orders guaranteed and ship within 24 hours.

Paperback. Etat : Very Good. 1. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Etat : very_good. Fast Free Shipping â" Very Good condition book with a firm cover and clean pages. Shows normal use and some light wear or limited notes markings. A solid, nice copy to enjoy.

Hardback. Etat : Good. Includes interviews with 2018 Nobel Prize Winners James Allison and Tasuku Honjo The way we treat cancer is about to change forever. This revolution--and it is precisely that--was sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer. Going forward, doctors will not use pharmaceuticals to attack tumors--not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient will treat the tumor. Based entirely on interviews with the investigators, this book is the story of the immuno-oncology pioneers. It's a story of failure, resurrection, and success. It's a story about science, it's a story about discovery, and intuition, and cunning. It's a peek into the lives and thoughts of some of the most gifted medical scientists on the planet. This is not a textbook. This is a life book. This technology will save/is saving lives, and the book celebrates the living, breathing, thinking, charming, arrogant, funny, obstinate, amazing human beings who are making immuno-oncology happen. The stories and lives shared in this book show readers the decades of devotion and passion it takes to imagine a better world and then make it happen. If this book motivates even one more similarly talented and visionary investigator to deliver on their promise it would be a wonderful success. -- Clifford A. Hudis, MD, FACP, FASCOChief Executive Officer, American Society of Clinical Oncology.…

Etat : very_good. Fast & Free Shipping â" Very Good condition book with a firm cover and clean pages. Shows normal use and some light wear or limited notes markings. A solid, nice copy to enjoy.

paperback. Etat : Good.

Paperback. Etat : Very Good. 1. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : good. Fast Free Shipping â" Good condition. It may show normal signs of use, such as light writing, highlighting, or library markings, but all pages are intact and the book is fully readable. A solid, complete copy that's ready to enjoy.

Etat : good. Fast Free Shipping â" Good condition. It may show normal signs of use, such as light writing, highlighting, or library markings, but all pages are intact and the book is fully readable. A solid, complete copy that's ready to enjoy.

Hardback. Etat : Very Good. Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…

Etat : very_good. Fast Free Shipping â" Very Good condition book with a firm cover and clean pages. Shows normal use and some light wear or limited notes markings. A solid, nice copy to enjoy.

Paperback. Etat : Good. Enjoy Your Cells is a new series of children's books from the acclaimed creative partnership of scientist/author Fran Balkwill and illustrator Mic Rolph. Once again, they use their unique brand of simple but scientifically accurate commentary and exuberantly colorful graphics to take young readers on an entertaining exploration of the amazing, hidden world of cells, proteins, and DNA. It's over ten years since Fran and Mic invented a new way of getting science across to children. Think what extraordinary advances have been made in biology in that time-and how often those discoveries made headlines. Stem cells, cloning, embryo transfer, emerging infections, vaccine development.here in these books are the basic facts behind the public debates. With these books, children will learn to enjoy their cells and current affairs at the same time. And they're getting information that has been written and reviewed by working scientists, so it's completely correct and up-to-date. Readers aged 7 and up will appreciate the stories' lively language and with help, even younger children will enjoy and learn from the jokes and illustrations-no expert required This series is a must for all elementary school students and those who care about educating them to be well-informed in a world of increasingly complex health-related and environmental issues.…

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc. Rolph, Mic (illustrateur).